Non-Hodgkin Lymphoma (NHL)

Latest News

Marginal zone lymphoma | Image: Atlas of Hematological Cytology
In R/R Marginal Zone Lymphoma, 90% Alive at 2 Years After Liso-Cel

June 24th 2025

In a cohort of TRANSCEND FL, the chimeric antigen receptor T-cell therapy liso-cel showed a 95% overall response rate in relapsed marginal zone lymphoma, offering hope for improved patient outcomes in challenging cases.

Cleveland Clinic Main Campus | Image: Cleveland Clinic
Optimizing Advanced Cancer Therapies and Addressing Logistical, Financial Challenges

June 19th 2025

large B-cell lymphoma | Image credit: Cleveland Clinic
Epcoritamab Plus Chemoimmunotherapy Yields 87% Response Rate in R/R DLBCL; 65% Proceed to Transplant

June 17th 2025

Follicular lymphoma | Image: The Follicular Lymphoma Foundation
A Look at Those With Durable Responses to Epcoritamab in LBCL

June 14th 2025

Ian W. Flinn, MD, PhD | Image credit: OneOncology
Fixed-Duration SC Mosunetuzumab Shows 83% PFS at 1 Year in Untreated HTB Follicular Lymphoma

June 10th 2025

Continuing Medical Education
View All
July 2nd 2025

Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care

1.5 Credits / Hematology, Hematologic Cancer, Oncology
July 2nd 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
July 2nd 2025

Closing Gaps in CLL Care: Managed Care Insights and Strategies

1.5 Credit / Hematologic Cancer, Oncology
July 2nd 2025

ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care

1.0 Credit / Oncology, Hematology, Hematologic Cancer
July 2nd 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health
July 2nd 2025

Overcoming Operational and Clinical Barriers in Multiple Myeloma: Managed Care Strategies for Antibody-Based Regimens

1.5 Credits / Hematologic Cancer, Hematology, Oncology

More News

Heart and DNA Image
July 22nd 2023

In DLBCL Treatment, Cardiovascular Comorbidities Warrant Careful Consideration

Jared Kaltwasser
The most common treatments come with significant cardiovascular risk, but study investigators suggest newer options might offer a more favorable risk profile.
Symbol of pancreatic cancer. Purple awareness ribbon: © Vitalii Vodolazskyi - stock.adobe.com
July 18th 2023

In Pancreatic DLBCL, Older Age, Distant Stage, Lack of Surgery Lead to Worse Outcomes

Jared Kaltwasser
Surgery can be difficult in such cases of diffuse large B-cell lymphoma (DLBCL), but it leads to significant better outcomes, study authors said.
Colorful cell interaction - tumor cell surrounded with immune cells (Generative AI): © Nevio - stock.adobe.com
July 11th 2023

Lymph Node Fibroblasts May Suppress T-Cell Function in DLBCL

Gianna Melillo
These findings from research into diffuse large B cell lymphoma (DLBCL) are based on analyses of human patients and a murine model.
PET/CT is a nuclear medicine device that uses a combination of PET (Positron Emission Tomography) and Computed Tomography technology to diagnose cancer. Brain and nervous system myocardial ischemia: © workphoto - stock.adobe.com
July 8th 2023

Complicated Case of DLBCL Shows Limits of 18F-FDG PET/CT Imaging

Jared Kaltwasser
Investigators said it is important for clinicians to interpret scans with knowledge of case-specific context for patients with diffuse large B-cell lymphoma (DLBCL).
White blood cells in leukemia, AI Generative: © Катерина Євтехова - stock.adobe.com
July 5th 2023

Evolutionary Dynamics Drive Behind Outcomes in Late DLBCL Relapses

Jared Kaltwasser
Serial biopsies help explain why patients with late relapses of diffuse large B-cell lymphoma (DLBCL) fare better than those with early relapses.
Topline Results Show Epcoritamab Offers 82% Response Rate in R/R Follicular Lymphoma
June 28th 2023

Topline Results Show Epcoritamab Offers 82% Response Rate in R/R Follicular Lymphoma

Mary Caffrey
The bispecific antibody received an accelerated approval in May to treat patients with R/R diffuse large B-cell lymphoma.
Finding solutions to complex cases from several perspectives. High angle shot of a group of medical practitioners having a discussion together in a hospital: © Kirsten D/peopleimages.com - stock.adobe.com
June 27th 2023

Patient Complaining of Abdominal Pain Found to Have Unusual Case of DLBCL

Jared Kaltwasser
The patient was put on chemotherapy, but then underwent surgical resection following an accident at home.
New Epcoritamab Data Show Strong Results in B-Cell Lymphomas
June 22nd 2023

New Epcoritamab Data Show Strong Results in B-Cell Lymphomas

Jared Kaltwasser
Data presented at the 2023 European Hematology Association Annual Meeting showed positive outcomes in patients with follicular lymphoma and large B-cell lymphoma, and further evaluation in diffuse large B-cell lymphoma is ongoing.
researchers in a lab
June 17th 2023

Epcoritamab Sparks Durable Responses in Phase 1/2 LBCL Trial

Jared Kaltwasser
At a median follow-up of 10.7 months, the overall response rate was 63.1%.
chest pain
June 16th 2023

Investigators Find DLBCL When Probing Apparent Intramural Hematoma

Jared Kaltwasser
The case report highlights the importance of considering diffuse large B-cell lymphoma (DLBCL) when evaluating patients with persistent periaortic fluid collections.
Epcoritamab Approval Expands Treatment Armamentarium for DLBCL
June 9th 2023

Epcoritamab Approval Expands Treatment Armamentarium for DLBCL

Mary Caffrey Rose McNulty
Tycel Phillips, MD, hematologist-oncologist at City of Hope in Duarte, CA, discussed the utility of epcoritamab in diffuse large B-cell lymphoma (DLBCL) and the potential impacts the bispecific antibody's recent approval will have in the community oncology setting.
depressed older man sitting with his head in his hand
June 8th 2023

Preexisting Mental Health Disorders Worsen DLBCL Prognosis

Laura Joszt, MA
Patients with depression, anxiety, or both at the time of diagnosis of diffuse large B-cell lymphoma (DLBCL) have worse overall survival and lymphoma-specific survival.
science background
June 7th 2023

Review: Advances in the Understanding of DLBCL Immunology Could Spark Novel Therapies

Jared Kaltwasser
New therapies could potentially target immune systems at play in certain types of diffuse large B-cell lymphoma.
FDA approved
May 19th 2023

Epcoritamab Approved by FDA to Treat R/R DLBCL

Mary Caffrey
Approval for the T-cell–engaging bispecific antibody came today from the FDA.
ASH 2022: Bispecific Antibodies
February 4th 2023

ASH 2022: Bispecific Antibodies

Mary Caffrey Hayden E. Klein
Coverage from the 64th Annual American Society of Hematology Meeting and Exposition, December 10-13, 2022, New Orleans, Louisiana.
Graphic with the words "Top 5 Clinical Spotlight Interviews of 2022"
December 29th 2022

Top 5 Clinical Spotlight Interviews of 2022

AJMC Staff
Throughout 2022, expert interviews on clinical topics covered cytogenetics in multiple myeloma, access to better treatments in diffuse large B-cell lymphoma, and challenges with devices in chronic obstructive pulmonary disease.
<12345>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo